Armin Heckel

This inventor holds 63 USPTO granted patents and 15 published patent applications, plus 7 CIPO patents and 31 EPO patents, primarily in Pharmaceutical Compounds (CPC class C07D). Top assignees: Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharma Kg, Boehringer Ingelheim Pharma Gmbh & Co Kg. Active years: 1987-2021.

USPTO Granted Patents = 63 (Patent Applications = 15)

% Patents Active = 92.1

CIPO Patents = 7 (Patent Applications = 3)

EPO Patents = 31 (Patent Applications = 29)

Average Co-Inventor Count = 5.2

ph-index = 11

Forward Citations = 408(Granted Patents)

Forward Citations (Not Self Cited) = 366(Dec 10, 2025)

Inventors with similar research interests:

Location History:

late of Biberach, DE (1995)
Biberach, DE (1987 - 2018)
Biberach an der Riss, DE (2014 - 2021)

Company Filing History:

28 out of 1,560

Boehringer Ingelheim International Gmbh

patents

12 out of 149

Boehringer Ingelheim Pharma Kg

patents

10 out of 194

Boehringer Ingelheim Pharma Gmbh & Co Kg

Evotec International Gmbh

patents

Years Active: 1987-2021

Loading Chart...

Areas of Expertise:

Benzimidazolium Compounds

Respiratory Diseases

Pharmaceutical Compositions

Heterocyclic Compounds

Pyrazine Derivatives

Indolinone Derivatives

Thienopyrimidines

Sulfoximine Substituted Quinazolines

Aryl-Containing Compounds

Carboxylic Acid Amides

Epithelial Sodium Channel Inhibitors

Fibrotic Diseases

63 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11179371 - Triazole benzamide derivatives as GPR142 agonists (2021-11-23),

2. 10221202 - Annelated phenoxyacetamides (2019-03-05),

3. 10155749 - Substituted benzimidazolium compounds useful in the treatment of respiratory diseases (2018-12-18),

4. 10154990 - Medicaments for the treatment or prevention of fibrotic diseases (2018-12-18),

5. 9981954 - 2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors (2018-05-29),

6. 9938256 - Annelated benzamides (2018-04-10),

7. 9932324 - Substituted benzimidazolium compounds useful in the treatment of respiratory diseases (2018-04-03),

8. 9920035 - Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof (2018-03-20),

9. 9708274 - Sulfoximine substituted quinazolines for pharmaceutical compositions (2017-07-18),

10. 9469631 - N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof (2016-10-18),

11. 9139577 - Sulfoximine substituted quinazolines for pharmaceutical compositions (2015-09-22),

12. 9126982 - Heterocyclic compounds, medicaments containing them, use and processes for the preparation thereof (2015-09-08),

13. 9096548 - Pyrazine amide compounds (2015-08-04),

14. 9078909 - Tertiary amines, medicaments containing said amines, use thereof and processes for the preparation thereof (2015-07-14),

15. 9073954 - 5-substituted benzimidazolium compounds (2015-07-07),

Title: The Innovative Journey of Armin Heckel: Pioneering Inventor in Biberach an der Riss

Introduction:

Armin Heckel, a distinguished inventor based in Biberach an der Riss, Germany, has left an indelible mark in the field of pharmaceutical innovations. With an impressive portfolio of 63 patents, his groundbreaking work has significantly impacted the treatment and prevention of diseases, particularly in the realm of type 2 diabetes.

Latest Patents:

Armin Heckel's latest patents showcase his ingenuity and commitment to advancing pharmacological research. His inventions include Triazole benzamide derivatives as GPR142 agonists, which have shown promising potential in targeting the GPR142 receptor to modulate its activity for disease management. Additionally, his work on annelated phenoxyacetamides underscores his dedication to developing novel compounds for medicinal purposes.

Career Highlights:

Armin Heckel has contributed his expertise to renowned companies such as Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharma KG. During his tenure at these organizations, he has spearheaded numerous research projects that have led to the development of pioneering pharmaceutical solutions.

Collaborations:

Throughout his career, Armin Heckel has collaborated closely with esteemed professionals in the field. Some of his notable coworkers include Joerg Kley and Gerald Juergen Roth, who have collectively worked towards achieving innovative breakthroughs in pharmaceutical science.

Conclusion:

In conclusion, Armin Heckel's unwavering dedication to innovation and his remarkable contributions to the field of pharmacology stand as a testament to his visionary approach towards inventing solutions that have the potential to transform healthcare. His legacy as an inventive luminary in Biberach an der Riss continues to inspire future generations of inventors and researchers in the pursuit of groundbreaking discoveries and advancements in medicine.